Jaguar Health (JAGX) investor relations material

Company overview and business model

• Develops plant-derived prescription therapies for complex GI diseases; Napo focuses on crofelemer and Mytesi, while animal health develops and commercializes non-prescription GI products.

• Future Pak became exclusive U.S. marketer of Mytesi and Canalevia-CA1 in Jan. 2026; manufacturing remains with Napo, and global crofelemer rights remain unencumbered.

• Magdalena Biosciences, a joint venture with Filament Health, is developing plant-derived prescription medicines for weight-gain prevention and mental health indications.

Financial performance and metrics

• Future Pak agreement provided $16.0M in non-dilutive capital in Jan. 2026, with $2.0M due upon post-closing conditions and up to $20M in milestone and other future payments.

• Since the prior S-3 filing, $183,059.51 of securities were sold; remaining prior-registration securities roll into this registration, with previously paid fees applied.

• Sept. 2026 debt exchanges included cancellation of a $175,016.36 LAS convertible note and full repayment and cancellation of Streeterville's 2025 note after a $5,049,909.26 balance reduction.

• Streeterville exchanges reduced the 2021 note balance by $1,678,320 on Sept. 23 and $3.4M on Sept. 25, 2026, in exchange for common shares.

Use of proceeds and capital allocation

• Net proceeds are intended for working capital and general corporate purposes, including R&D, capital, operating and administrative expenditures, and potentially strategic alternatives.

• Pending use, proceeds are intended for investment in high-quality, short-term, interest-bearing securities; management retains discretion over allocation.